3D Systems (DDD) Q1 2026: Healthcare Surges 21%, Denture Launch Expands Multibillion-Dollar Market
3D Systems delivered a decisive turnaround in Q1, with healthcare now outpacing industrial as the largest segment and dental product launches unlocking new addressable markets. Margin expansion and disciplined cost controls signal a structurally stronger business, while aerospace and defense demand accelerates capacity investments. Management’s measured outlook reflects both broadening sector adoption and persistent macro volatility, setting the stage for a pivotal year of execution.
Summary
- Healthcare Overtakes Industrial: Medical and dental momentum drives segment leadership and recurring growth base.
- Denture Platform Unlocks New Markets: Expanded regulatory approvals and rapid adoption signal durable revenue lift.
- Aerospace and Defense Demand Outpaces Capacity: Facility expansion and material innovation position DDD for sustained high-value growth.
Business Overview
3D Systems is a leading provider of additive manufacturing solutions, generating revenue from the sale of 3D printers, proprietary materials, parts manufacturing, and related services. Its business is organized into two main segments: Healthcare Solutions (including dental, medical devices, and surgical planning) and Industrial Solutions (focused on aerospace, defense, automotive, and semiconductors). The company’s strategy targets high-reliability, regulated markets with significant barriers to entry and recurring consumables demand.
Performance Analysis
3D Systems posted 11% year-over-year revenue growth in Q1, marking a clear inflection after several challenging quarters. The healthcare segment grew 21% year-over-year, surpassing industrial for the first time and reflecting robust demand in both dental and medtech. Notably, printer, materials, and parts manufacturing each delivered double-digit growth, underscoring the breadth of the recovery across the portfolio.
Gross margin expanded by six percentage points year-over-year to 36.1%, driven by improved manufacturing absorption, favorable consumables mix, and product mix shift toward higher-margin healthcare and metal printers. Operating expenses dropped 35% year-over-year, reflecting the full impact of a six-quarter cost optimization program and the wind-down of elevated R&D spend. Adjusted EBITDA swung to a $2.1 million profit, a $26 million improvement, demonstrating operational leverage as volumes recover.
- Healthcare Leadership Shift: Healthcare’s 21% growth now makes it the largest segment, powered by dental and medtech expansion.
- Margin Recovery: Gross margin gains reflect both volume leverage and mix improvement toward consumables and advanced printers.
- Cost Structure Reset: Operating expenses fell sharply as cost initiatives reached maturity, supporting positive EBITDA turnaround.
Despite supply chain headwinds and isolated customer disruptions, execution was broadly resilient. The company’s cash position remains solid, with $86.5 million on hand and manageable near-term debt obligations. Overall, Q1 marks a structural improvement in profitability and validates the company’s multi-year portfolio refresh strategy.
Executive Commentary
"The additive manufacturing industry is now beginning to emerge from a multi-year trough... Our company's targeted investments in research and development, which we sustained in the face of intense cost pressures over this period, are now enabling us to introduce a completely refreshed portfolio of new products... No company in our industry can match this range of technologies, nor the product performance that these systems can deliver."
Dr. Jeffrey Graves, President and CEO
"First quarter consolidated revenue was $95.5 million, an increase of 11% year-over-year, demonstrating a solid return to revenue growth in the quarter... Non-GAAP gross margin was 36.1%, up six percentage points from the prior year period when adjusting for software divestitures. Non-GAAP operating expenses were $36.6 million, down 35% or $20.1 million from the prior year period."
Phyllis Nordstrom, Chief Financial Officer
Strategic Positioning
1. Healthcare Expansion and Recurring Revenue
Healthcare now leads 3D Systems’ revenue mix, with both medtech and dental showing sustainable double-digit growth. The dental portfolio, particularly the NextDent 300 denture printer, is unlocking new recurring material sales and expanding the company’s addressable market following US and EU regulatory approvals. The medtech franchise benefits from regulatory barriers and rising demand for personalized implants and surgical planning, creating a defensible, high-margin growth engine.
2. Aerospace and Defense: Capacity and Material Innovation
Aerospace and defense revenue grew over 20% year-over-year, outpacing other industrial verticals. The company’s dual-path metal manufacturing—direct metal printing (DMP) and SLA-based investment casting—uniquely positions it for high-reliability, mission-critical applications in propulsion, satellites, and defense systems. The expansion of the Littleton, Colorado facility by 80,000 square feet is a direct response to surging demand, focusing on advanced materials like titanium and nickel alloys for propulsion and naval uses.
3. Portfolio Refresh and R&D Leverage
3D Systems’ multi-year R&D investment cycle is now yielding commercial results, with a refreshed product lineup in both polymers and metals. The company is pivoting from broad portfolio redevelopment to targeted enhancements, which will moderate R&D spend and support margin expansion going forward. The successful launch cadence—denture printers, new jewelry systems, and large-frame metal printers—demonstrates improved innovation-to-commercialization velocity.
4. Cost Discipline and Operating Leverage
Having delivered over $55 million in annualized cost savings, 3D Systems has reset its cost base. Operating expenses are now structurally lower, providing a buffer against macro volatility and supporting positive EBITDA even at modest revenue growth rates. This operational discipline frees up capacity for selective growth investments while maintaining financial flexibility.
5. Market Timing and Adoption Inflection
Management sees the additive manufacturing market emerging from a prolonged downturn, with “green shoots” across healthcare and industrial. Broader sector adoption, especially in dental and aerospace, coincides with 3D Systems’ refreshed portfolio, positioning the company to capture share as capital spending recovers and digital workflows become standard.
Key Considerations
This quarter marks a turning point for 3D Systems, as segment leadership shifts to healthcare and new product launches drive both market expansion and recurring revenue streams. The company’s ability to balance innovation with cost discipline is central to its improved profitability and future scalability.
Key Considerations:
- Denture Platform Scaling: NextDent 300’s rapid adoption and expanded regulatory footprint open a multibillion-dollar market and build a durable material revenue stream.
- Healthcare Defensibility: Regulatory barriers and personalized medicine trends support sustainable, high-margin growth in medtech and dental.
- Aerospace and Defense Backlog: Facility expansion reflects real customer pull across propulsion, satellite, and naval segments, with material science as a key differentiator.
- Cost Structure Reset: Completion of six-quarter cost program locks in operating leverage and supports margin resilience through cycles.
- Macro Volatility Caution: Management’s measured guide reflects both optimism for demand and recognition of logistical and geopolitical risks.
Risks
Geopolitical instability and supply chain disruptions, particularly in the Middle East, continue to challenge logistics and regional demand, especially for jewelry and certain industrial verticals. Healthcare seasonality and elective procedure timing could introduce quarterly volatility, while the pace of sector adoption and capital spending recovery remains uncertain. Execution risk around scaling new products and facilities is heightened as demand accelerates.
Forward Outlook
For Q2, 3D Systems guided to:
- Revenue of $93 to $95 million
- Adjusted EBITDA loss of $2 to $4 million
For full-year 2026, management aims for:
- Break-even or better adjusted EBITDA
Management emphasized:
- Seasonal softness in healthcare due to elective procedure timing
- Continued cost discipline and stable operating expenses
- Measured guidance approach given global volatility and logistics complexity
Takeaways
3D Systems has emerged from a multi-year trough with a structurally stronger business, led by healthcare and high-value industrial demand. Execution on new product launches and capacity expansion will be critical to sustaining momentum as sector adoption accelerates.
- Healthcare and Dental Now Anchor Growth: Segment leadership and recurring consumables revenue provide a more stable base for future expansion.
- Operational Leverage Realized: Cost structure reset and margin recovery support positive EBITDA and improved cash flow visibility.
- Execution Watchpoint: Monitor scale-up of new facilities and product adoption, as well as resilience to macro and supply chain shocks in coming quarters.
Conclusion
3D Systems delivered a pivotal quarter, shifting its growth engine to healthcare and demonstrating the payoff from sustained R&D and cost discipline. With new products gaining traction and capacity investments underway, the company is positioned to capitalize on accelerating adoption in its core markets—though execution and external risks remain front of mind for investors.
Industry Read-Through
3D Systems’ results signal a broader inflection in additive manufacturing, especially in regulated, high-reliability sectors like healthcare and aerospace. The shift toward digital dental workflows and personalized implants is accelerating, suggesting sustained demand for materials and recurring services across the industry. Aerospace and defense’s rapid adoption of advanced metal printing underscores the importance of dual-path manufacturing (DMP and SLA) and materials innovation—key competitive levers for peers. Cost discipline and portfolio refresh cycles will be critical for other players seeking to move from cyclical to structural growth as the sector recovers from its downturn.